Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1994-02-15
1996-04-09
Cook, Rebecca
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514213, 514409, 514428, 514429, 514613, 514617, 514212, 5142335, 5142352, 5142358, 5142378, 514307, 514319, 514323, 514324, 514412, 514414, 514432, 514438, 514443, 514444, 514451, 514462, 514469, A61K 3138, A61K 3140
Patent
active
055062571
ABSTRACT:
The present invention provides methods for blocking sodium channels in cardiac or neuronal tissue using aminocyclohexylamides. This invention also provides kits including aminocyclohexylamides and instructions for the use of the compounds for the treatment of arrhythmia or for the inducement of local anaesthesia.
REFERENCES:
patent: 4438130 (1984-03-01), Kaplan
patent: 4508911 (1985-04-01), Kaplan
patent: 4579863 (1986-04-01), Horwell et al.
patent: 4598087 (1986-07-01), Horwell
patent: 4656182 (1987-04-01), Horwell
patent: 4663343 (1987-05-01), Horwell
patent: 4677122 (1987-06-01), Horwell
patent: 4737493 (1988-04-01), Horwell
Abraham et al., "Antiarrhythmic Properties of Tetrodotoxin Against Occlusion-Induced Arrhythmias in the Rat: A Novel Approach to the Study of the Antiarrhythmic Effects of Ventricular Sodium Channel Blockade," J. Pharmacol. Exp. Ther. 251:1166-1173, 1989.
Alzheimer and Ten Bruggencate, "Nonopioid Actions of the .kappa.-Opioid Receptor Agonists, U 50488H and U 69593, on Electrophysiologic Properties of Hippocampal CA3 Neurons in Vitro," J. Pharmacol. Exp. Ther. 255:900-905, 1990.
Clark et al., "Highly Selective .kappa. Opioid Analgesics. Synthesis and Structure-Activity Relationships of Novel N-[2-Aminocyclohexyl)aryl]acetamide and N-[(2-Aminocyclohexyl)aryloxy]acetamide Derivatives," J. Med. Chem. 31:831-836, 1988.
Clark et al., "PD117302: a selective agonist for the .kappa.-opioid receptor," Br. J. Pharmacol. 93:618-626, 1988.
Curtis and Walker, "Quantification of arrhythmias using scoring systems: an examination of seven scores in an in vivo model of regional myocardial ischaemia," Cardiovasc. Res. 22:656-665, 1988.
Halfpenny et al., "Highly Selective .kappa.-Opioid Analgesics. 2. Synthesis and Structure-Activity Relationships of Novel N-[(2-Aminocyclohexyl)aryl]acetamide Derivatives," J. Med. Chem. 32:1620-1626, 1989.
Halfpenny et al., "Highly Selective .kappa.-Opioid Analgesics. 3. Synthesis and Structure-Activity Relationships of Novel N-[2-(1-Pyrrolidinyl)-4- or -5-substituted-cyclohexyl]arylacetamide Derivatives," J. Med. Chem. 33:286-291, 1990.
Howard and Walker, "Electrical Stimulation Studies with Quinacainol, a Putative 1C Agent, in the Anaesthetised Rat," Proc. West. Pharmacol. Soc. 33:123-127, 1990.
Hunter et al., "CI-977, a novel and selective agonist for the .kappa.-opioid receptor," Br. J. Pharmacol. 101:183-189, 1990.
Leighton et al., "Pharmacological profile of PD 117302, a selective .kappa.-opioid agonist," Br. J. Pharmacol. 92:915-922, 1987.
Ma et al., "Synthesis and analgesic activity of analogs of U-50488, an opiate kappa-agonist," Chemical Abstracts 117::48285, p. 906, 1992.
Meecham et al., "An in vitro profile of activity for the (+) and (-) enantiomers of spiradoline and PD117302," Eur. J. Pharmacol. 173:151-157, 1989.
Penz et al., "A New ECG Measure (RSh) for Detecting Possible Sodium Channel Blockade in Vivo in Rats," J. Pharmacol. Methods 27:51-58, 1992.
Pugsley et al., "Antiarrhythmic effects of U-50, 488H in rats subject to coronary artery occlusion," Eur. J. Pharmacol. 212:15-19, 1992.
Pugsley et al, "Cardiovascular actions of the .kappa.-agonist, U-50, 488H, in the absence and presence of opioid receptor blockade" Br. J. Pharmacol. 105:521-526, 1992.
Pugsley et al., "Electrophysiological and antiarrhythmic actions of the .kappa. agonist PD 129290, and its R,R(+) -enantiomer, PD 129289," Br. J. Pharmacol. 110:1579-1585, 1993.
Pugsley et al., "Cardiovascular Actions of U50, 488H, and Related Kappa Agonists," Cardiovascular Drug Reviews 11:151-164, 1993.
Sarne et al., "Anti-arrhythmic activities of opioid agonists and antagonists and their stereoisomers," Br. J. Pharmacol. 102:696-698, 1991.
Singh et al., "The anticonvulsant action of CI-977, a selective .kappa.-opioid receptor agonist: a possible involvement of the glycine/NMDA receptor complex," Eur. J. Pharmacol. 191:477-480, 1990.
Sitsapesan and Parratt, "The effects of drugs interacting with opioid receptors on the early ventricular arrhythmias arising from myocardial ischaemia," Br. J. Pharmacol. 97:795-800, 1989.
Szmuszkovicz and Von Voigtlander, "Benzeneacetamide Amines: Structurally Novel Non-M.mu. Opioids," J. Med Chem. 25:1125-1126, 1982.
Von Voigtlander et al., "U-50,488: A Selective and Structurally Novel Non-Mu (Kappa) Opioid Agonist," J. Pharmacol. Exp. Ther. 224:7-12, 1983.
Wong et al., "Effects of Drugs Interacting with Opioid Receptors During Normal Perfusion or Ischemia and Reperfusion in the Isolated Rat Heart-an Attempt to Identify Cardiac Opioid Receptor Subtype(s) Involved in Arrhythmogenesis," J. Mol. Cell. Cardiol. 22:1167-1175, 1990.
MacLeod Bernard A.
Walker Michael J. A.
Wall Richard A.
Cook Rebecca
University of British Columbia
LandOfFree
Aminocyclohexylamides for antiarrhythmic and anaesthetic uses does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Aminocyclohexylamides for antiarrhythmic and anaesthetic uses, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Aminocyclohexylamides for antiarrhythmic and anaesthetic uses will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-139437